Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Antiviral Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TMPRSS4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TMPRSS4 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View TMPRSS4 Products |
| Gene Delivery | TMPRSS4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Preserve native conformation for functional assays. |
View TMPRSS4 Products |
| Benchmark Ab | Anti-TMPRSS4 (Sequence-Verified Research Control) Recombinant positive control for binding, blocking and imaging assays. |
View TMPRSS4 Products |
| Validator | TMPRSS4 siRNA Set (3 Unique Sequences) For knockdown verification and specificity controls. |
View TMPRSS4 Products |
| Related Target A | TMPRSS2, TMPRSS3 Critical for selectivity counter-screening against other TTSP family members (serine protease domain conservation). |
View TMPRSS2 Products, View TMPRSS3 Products |
| Related Target B | MET, ST14 / Matriptase Synergistic pathway analysis in cancer metastasis and EMT progression; TTSP subfamily cross-reactivity profiling. |
View MET Products, View ST14 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Counter Screening (Selectivity) | Homolog panel proteins (TMPRSS2, TMPRSS3, ST14, Hepsin, Matriptase) strictly verified by theoretical MW and high purity; ready for competitive binding assays. |
| Complex Membrane Conformation | Lentivirus Premade Particles for stable cell line construction, preserving native folding and topology. |
| Enzymatic Assay Reliability | HEK293 Expressed (Native Glycosylation) ECD proteins to ensure proper folding of the catalytic domain. |
| False Positives in Assays | Validated siRNA included for cellular specificity checks and loss-of-signal confirmation. |
| Cross-species Evaluation (IND-enabling) | Human/Mouse/Cynomolgus TMPRSS4 ortholog proteins available with >95% purity; sequence-aligned ECD boundaries for epitope conservation analysis. |
| Lack of Positive Controls | Sequence-verified recombinant Anti-TMPRSS4 monoclonal antibody included as assay benchmark and control. |
Live TMPRSS4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TMPRSS4 therapeutics is intensifying, with major players shifting focus from purely antiviral hypotheses to broad oncological applications including Antibody-Drug Conjugates (ADCs), function-blocking monoclonal antibodies, and targeted small molecule inhibitors. As a Type II transmembrane serine protease highly upregulated in pancreatic, gastric, lung, and colorectal cancers, TMPRSS4 is a primary driver of the epithelial-mesenchymal transition (EMT) and metastasis. As first-generation therapies advance through preclinical and early clinical stages, the next wave of R&D is targeting combinatorial strategies with immune checkpoint inhibitors and highly selective modalities to counteract tumor invasiveness without disrupting normal physiology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic & Biotech Spin-offs, Protease-focused Discovery | Pancreatic Cancer, NSCLC, Advanced Carcinomas | Selectivity Assay (Need high-purity ECD-Fc and WT vs mutant protease domains for enzymatic screens) |
| Monoclonal Antibodies (including function-blocking) | Early Preclinical Innovators, Immuno-oncology Developers | Solid Tumors (Metastatic) | Binding Affinity & Cross-reactivity Panel (Need native glycosylation protein and TTSP orthologs) |
| Antibody-Drug Conjugates (ADC) | Emerging Biotechs, Oncology-focused Pharma | Gastric Cancer, Colorectal Cancer, Pancreatic Cancer | Internalization Assay (Need high-purity ECD-Fc for antibody generation; Lentivirus stable lines for cell-based uptake) |
| RNAi / ASO | Specialty Oligo Biopharmas | Viral Infection / Oncology | Knockdown Validation (Need Lentivirus cell lines & siRNA set) |
| Bispecifics | Discovery Stage Pipeline | Refractory GI Tumors | Heterodimer Validation (Need cross-reactive Abs & target panels) |
| Combination Therapy (IO + Targeted) | IO + Protease Inhibitor Programs | Immunotherapy-resistant Tumors | Stable Cell Line Construction (Lentivirus for co-culture assays with immune cells) |